Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 6:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Assessment only Control Clear all
Completed Not applicable Interventional

An Emotion-Focused Intervention for Glycemic Control in T2D

NCT03553680
View directory record Official record
Conditions
Type2 Diabetes
Interventions
Emotion-Focused CBT
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Sep 3, 2026, 6:26 AM EDT
Completed Phase 1Phase 2 Interventional

Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)

NCT00094380
View directory record Official record
Conditions
Lupus Erythematosus, Systemic, Lupus Nephritis
Interventions
CTLA4-IgG4m (RG2077), Cyclophosphamide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 3, 2026, 6:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of a Combined Nature-based and Virtual Mindfulness Intervention on Perceived Stress in Healthcare Workers

NCT04846790
View directory record Official record
Conditions
Stress, Psychological, Sleep Disturbance, Burnout, Caregiver, Posttraumatic Stress Disorder, Anxiety, Depression
Interventions
Nature Only, Nature+Mindfulness
Behavioral
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Sep 3, 2026, 6:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Sequential Single and Multiple Ascending Dose (SAD/MAD) Study of SK10 Powders in Healthy Adult Subjects

NCT06026397
View directory record Official record
Conditions
Chemotherapy-induced Diarrhea
Interventions
SK10, Placebo
Drug
Lead sponsor
Guangzhou Zhiyi Biotechnology Co., Ltd.
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 3, 2026, 6:26 AM EDT
Not yet recruiting Phase 4 Interventional

Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1

NCT07554417
View directory record Official record
Conditions
GLP - 1, Obesity & Overweight, Muscle Loss, Exercise Intervention, Dietary Assessment
Interventions
Semaglutide, Dietary Counseling, Exercise
Drug · Behavioral
Lead sponsor
William Marsh Rice University
Other
Eligibility
40 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 3, 2026, 6:26 AM EDT
Completed Phase 3 Interventional Results available

ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

NCT03056040
View directory record Official record
Conditions
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
Ravulizumab, Eculizumab
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
5
States / cities
Duarte, California • Los Angeles, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Sep 3, 2026, 6:26 AM EDT
Terminated Phase 1 Interventional

Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus

NCT01164917
View directory record Official record
Conditions
Cutaneous Lupus, Discoid Lupus, Lupus, Systemic Lupus Erythematosus
Interventions
AMG811, AMG811 Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Santa Monica, California • Stanford, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Sep 3, 2026, 6:26 AM EDT
Active, not recruiting Not applicable Interventional

Wearables for the Bladder: an In-home Treatment Feasibility Pilot Study

NCT05715268
View directory record Official record
Conditions
Multiple Sclerosis, Urinary Bladder, Overactive
Interventions
WeB, Standard pelvic floor physical therapy
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 3, 2026, 6:26 AM EDT
Not listed Not applicable Interventional

Safety and Efficacy Study of Magnetic Fields to Treat Alzheimer's Disease

NCT01195389
View directory record Official record
Conditions
Alzheimer's Dementia
Interventions
Resonator
Device
Lead sponsor
pico-tesla Magnetic Therapies, LLC
Industry
Eligibility
55 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 7, 2011 · Synced Sep 3, 2026, 6:26 AM EDT
Completed Phase 1 Interventional

Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder

NCT02286817
View directory record Official record
Conditions
Attention-deficit Hyperactivity Disorder (ADHD)
Interventions
NFC-1
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
12 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 3, 2026, 6:26 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY

NCT02665221
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
No Treatment Arm, Topical Preparation H arm
Other · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Sep 3, 2026, 6:26 AM EDT
Completed Phase 2 Interventional Results available

Fasitibant Intra-articular Injection in Patients With Symptomatic Osteoarthritis of the Knee

NCT02205814
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Fasitibant- low dose, Fasitibant- intermediate dose, Fasitibant- high dose, Placebo comparator
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
40 Years to 80 Years
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
9
States / cities
Tucson, Arizona • Englewood, Colorado • DeLand, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Sep 3, 2026, 6:26 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea

NCT00995787
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
AZD1656, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2010 · Synced Sep 3, 2026, 6:26 AM EDT
Not listed Phase 4 Interventional

Assessing Decision Maker Tools for Asthma: the Asthma APGAR

NCT01446315
View directory record Official record
Conditions
Asthma
Interventions
Use of Asthma APGAR system and tools, Asthma APGAR tools
Behavioral
Lead sponsor
Olmsted Medical Center
Other
Eligibility
5 Years to 60 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Sep 3, 2026, 6:26 AM EDT
Completed Not applicable Interventional

Virtual Weight Control Program Tailored for Adults With Type 2 Diabetes (VITAL)

NCT04804774
View directory record Official record
Conditions
Type2 Diabetes, Overweight and Obesity
Interventions
WW program modified for people with Type 2 diabetes
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 70 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Gainesville, Florida • Baton Rouge, Louisiana • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Sep 3, 2026, 6:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of LY3023703 Testing Pain Relief After Wisdom Teeth Removal

NCT01872910
View directory record Official record
Conditions
Acute Pain
Interventions
Placebo, LY3023703, Celecoxib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2019 · Synced Sep 3, 2026, 6:26 AM EDT
Completed Not applicable Interventional Results available

Family-Based Prevention Program for Childhood Anxiety

NCT00078728
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Family-Based Anxiety Prevention Program, Evaluation only
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
7 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Sep 3, 2026, 6:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ONO-7746 Study in Healthy Adult Subjects

NCT00956371
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
ONO-7746
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2012 · Synced Sep 3, 2026, 6:26 AM EDT
Completed Not applicable Interventional

Novel PAradigm to Improve Inflammatory Burden in ESRD (rePAIR): A Pilot and Feasibility Randomized Controlled Trial

NCT03241511
View directory record Official record
Conditions
Chronic Periodontitis, End Stage Renal Disease
Interventions
Test
Other
Lead sponsor
UConn Health
Other
Eligibility
21 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 3, 2026, 6:26 AM EDT
Completed Phase 4 Interventional Results available

Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis

NCT01119287
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Dexamethasone 0.1% ophthalmic suspension, Olopatadine hydrochloride 0.1% ophthalmic solution, Inactive ingredients, used as placebo
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years to 64 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Sep 3, 2026, 6:26 AM EDT
Completed Not applicable Interventional

Evaluating the Cost Effectiveness of STEADI

NCT05390736
View directory record Official record
Conditions
Accidental Fall
Interventions
Gait and balance assessment, Medication review, Comorbidity review, Fall history, Assessment of feet/footwear, Assessment of visual acuity, Home safety risk assessment, Vitamin D Deficiency
Behavioral
Lead sponsor
National Opinion Research Center
Other
Eligibility
65 Years and older
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Sep 3, 2026, 6:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study of Progerinin in Healthy Volunteers

NCT04512963
View directory record Official record
Conditions
Hutchinson-Gilford Progeria Syndrome, Werner Syndrome
Interventions
Progerinin, Placebo
Drug
Lead sponsor
PRG Science & Technology Co., Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Sep 3, 2026, 6:26 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Brain Health Virtual Reality Study

NCT06124339
View directory record Official record
Conditions
Aging, Aging Problems, Memory Loss, Memory Impairment, Memory Disorders in Old Age, Memory Disorder, Spatial, Memory Disorders, Mild Cognitive Impairment, Cognitive Decline, Cognitive Change, Cognition Disorders in Old Age
Interventions
Physical Activity, Cognitive Activity (VR), Physical and Cognitive Activity
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 3, 2026, 6:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult Subjects

NCT00789568
View directory record Official record
Conditions
Phenylketonuria
Interventions
sapropterin dihydrochloride, Moxifloxacin, Moxifloxacin placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Sep 3, 2026, 6:26 AM EDT